Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay005 for Behçet's disease oral ulcers (phase II)
CTR20201324Phase 2Terminated
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mufemilast in Behçet's disease (BD), sponsored by Ganzhou Hemay Pharmaceutical Co., Ltd.. Started Nov 2020; status: terminated.
02
Drugs
mufemilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on CTR20201324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201324.